There is growing evidence for a connection between inflammation and tumor development, and the nuclear factor kappa B (NF-B), a proinflammatory transcription factor, is hypothesized to promote tumorigenesis. Although the genetic evidence for the hypothesis has been lacking, recent papers have lent credence to this hypothesis. It has been reported that constitutive NF-B activation in inflammatory bowel diseases ( 
Introduction
Epidemiological studies revealed that chronic inflammation predisposes individuals to different cancers. The triggers of chronic inflammation that increase cancer risk include microbial infections (i.e. Helicobacter pylori for gastric cancer), autoimmune diseases (i.e. inflammatory bowel disease for colon cancer), and cryptogenic inflammatory conditions (i.e. ulcerative colitis for colorectal cancer). Accordingly, administration of non-steroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of several tumors (1, 2) . In recent years, though studies have revealed the connection between inflammation and carcinogenesis (3) (4) (5) (6) , the mechanistic links between the two is just beginning to emerge.
Genetic approaches have proven the role of key components of inflammation such as hematopoietic growth factors (MCSF), primary inflammatory cytokines (IL-1, TNF), IL-6, and the nuclear factor-B (NF-B) family members (7) (8) (9) in carcinogenesis. NF-B has been shown to be activated in all cells, where it regulates expression of diverse target genes that promote cell proliferation, regulate immune and inflammatory response, and contribute to pathogenesis of various diseases, including cancer (10) (11) (12) . This review will focus on new data that have emerged over the last couple of years implicating NF-B signaling pathways in carcinogneneisis of colorectal cancer (CRC), the one of the most common fatal malignancies worldwide (13) .
The NF-B family and signaling pathway NF-B signaling pathway is a complex network that regulates a cellular pathway involved in a myriad of physiological and pathological scenarios. The detailed description of NF-B structure, function and regulation is beyond the scope of this review (see recent review (14) (15) (16) ). Briefly, five homologous subunits have been identified in mammals: RelA/p65, c-Rel, RelB, NF-B1/p50, and NF-B2/p52. p50 and p52 are produced by processing of their precursors NF-B1 p105 and NF-B2 p100, respectively. All of the NF-B family members contain their Rel homology domain (RHD), which is required for DNA binding, homo-and heterodimerization, nuclear localization and inhibitor (IB) binding (17, 18) . NF-B signaling pathway is regulated by IB family. There are seven IB family members -IB, IB, IB, IB, Bcl-3 and the precursor proteins p100 and p105. IBs bind to NF-B dimers and block their nuclear localization, thereby causing their cytoplasmic retention. Most stimuli activate NF-B through IB kinase-dependent (IKK-dependent) phosphorylation, polyubiquitination and subsequent proteasomal degradation of IB proteins. The liberation of NF-B allows translocation of heterodimer to the nucleus, where it can regulate the expression of specific genes typically involved in immune and inflammatory responses and in cell growth control (17, 19) .
Many divergent stimuli activate two NF-B pathways (29) (Figure 1 ). The activation events that modulate these pathways are mediated by a family of inhibitory kappa B kineses (IKKs); which consists of three core subunits, the catalytic subunits IKK and IKK and several copies of a regulatory subunit IKK. The first, known as the classical or canonical pathway depends on IKK, IKKβ activation, phosphorylates mainly IBα but also IBβ and IBε, which are present in the cytoplasm of unstimulated cells and undergo stimulus-induced degradation and resynthesis (20, 21) . Following stimulation with the various inflammatory stimuli, including certain members of tumor necrosis factor α (TNF-) cytokine family, IL-1, Toll-like receptor ligands (22) (23) (24) (25) , the IB molecules are phosphorylated by the IKK complex, which leads to their degradation by the proteasome pathway (26) . This pathway mostly targets p50: RelA and p50: c-Rel dimers, which translocate to the nucleus and activate the transcription of various target genes (18, 27) . The activation of canonical pathway is essential for innate immunity and responsible for the inhibition of apoptosis under most conditions in response to infections or exposure to proinflammatory cytokines (28, 29 Intermediated kinases convey signals to the IκB complex formed by IκB, IκB, IκB, and proteasome degradation. P105/RelA is processed to p50/RelA, which translate to the nucleus and bind promoters of genes regulating innate immunity and cell survival. (B) The alternative pathway is activated through IKK by lymphotoxin receptor (LTR), CD40 ligand (CD40L), and other TNF family members (BAFF), which activate P100/RelB for processing into p52/RelB heterodimers. The p52/RelB heterodimers then translates into the nucleus to bind the promoter of genes regulating lymphoid organesis and maintain the malignant phenotype in some cancers. Inhibitors of NF-κB pathway activation under clinical and preclinical investigation include IKK and proteasome antagonists. ligand, receptor-activated NF-B ligand (RANKL), and lymphotoxin  through another proteasome-dependent mechanism, dependent on IKKα and upstream kinase (NIK), thereby leading to the proteasome-dependent processing of the RelB inhibitor NF-B2 p100, resulting in RelB-p50 nuclear translocation and DNA binding (22) . The p52/RelB dimers have higher affinity for distinct B elements (29) . This pathway plays a crucial role in controlling the development and function of secondary lymphoid organs (29, 32) .
The activation of both pathways relies on the inducible phosphorylation of IB inhibitory proteins (IBs and p100) by the IKK complex. Both pathways regulate cell survival and death (33) , and now have been implicated in carcinogenesis (34, 35) . In addition to the classical IKKmediated NF-B activation, it has been shown that certain novel pathway can activate NF-B by IKK-independent such as UV and hydrogen peroxide (H 2 O 2 ) induced NF-B activation (36) (37) (38) .
NF-B links inflammation to cancer
A causal relation between inflammation and cancer has been proposed by Virchow, who hypothesized that malignant neoplasm arise at regions of chronic inflammation, reasoned that various "irritants" caused tissue injury, inflammation, and increased cell proliferation (39, 40) . It has been estimated that more than 15% of all malignancies are initiated by chronic inflammatory disease (40) (41) (42) (43) (44) (45) . In Table 1 , an outline is given of inflammation that has been associated with cancer development: skin inflammation with squamous cell carcinoma, viral hepatitis with liver cancer and inflammatory bowel disease with colorectal cancer. Although the exact mechanism of inflammation initiating neoplasm is still not completely understood, the NF-B could well be an important player in this process since it is activated in chronic inflammation and its constitutive activation in cancers as mentioned follow.
Populations in developing countries are susceptible to cancers caused by infectious agents. The organs and cancer associated pathogens include liver (hepatitis B virus (HBV) and hepatitis C virus (HCV)), biliary tract (Opisthorchis viverrini, Clonorchis sinensis), stomach (Helicobacter pylori (H pylori)), uterine cervix (human papillomavirus (HPV)), nasopharynx (Epstein-Barr virus (EBV)), and urinary bladder (Schistosoma hematobium). The proportion of cancer deaths attributable to these infectious agents has been estimated to range from 20% to 25% in developing countries and 7% to 10% in more industrialized countries (46) . The first evidence implicating NF-B activation mediated pathogen-induced carcinogenesis was identification of the REV-T viral oncogene that causes avian reticuloendothelial lymphomatosis, v-Rel, which shares a Rel transactivation domain with the mammalian homologues NF-family members (47) . Hepatitis B X protein and hepatitis C 5A and core proteins have been shown to activate NF-B and are implicated in carcinogenesis of hepatocellular carcinoma (48) . In addition, the specific subtypes of human papillomavirus (HPV) infection are potentially oncogenic in the uterine cervix, vagina, vulva, anus, penis, skin, and oropharynx (49, 50) . HPV genes E6 and E7, the main transforming genes of oncogenic strains, have been implicated in NF-B activation by inactivating p53 and Rb tumor suppressor genes. Besides, some chemical and physical carcinogens implicated in initiation and/or promotion of human cancer can also activate (51, 52) . Recently, talc use in women has also been implicated in promotion of ovarian cancer (53) , but the mechanism needs to be further explored. Taken together, NF-B seems to have some functions that are necessary for links inflammation with cancer.
Role of NF-B in colorectal cancer
Chronic inflammation and colorectal cancer Ulcerative colitis (UC) and Crohn's disease (CD) are the two major forms of inflammatory bowel diseases (IBDs). IBD primarily represents an inflammatory disorder affecting the intestine, resulting in diarrhoea, anaemia and fatigue, associated with increased risk of neoplasia experienced by patients with chronic inflammation (54) . Underlying mechanisms have been the focus of a limited set of studies to date. In IBDs, long term inflammation is thought to sustain cancer initiation by the continuous release of reactive oxygen species (ROS), which are thought to ultimately cause DNA damage and the dysplastic degeneration of the repairing epithelium (55) . The inflammatory site is characterized by the release of cytokines, growth factors, proteases and ROS, which regulate the sequential recruitment of leukocytes and stimulate endothelial cells and fibroblast to divide and produce components for tissue remodeling. It has been proposed that noxious compounds released during chronic inflammation damage DNA and/or alter cell survival, results in carcinogenesis of CRC (56) . NSAIDs have been shown to reduce adenoma and colon cancer development in patients with IBD and hereditary colon cancer (57, 58) . In addition, COX2 inhibitors have been shown to prevent the recurrence of both adenomas and sporadic adenomatous plyps in patients with predisposition (59, 60) . However, there are growing evidence that cytokines released during inflammation may contribute to cancer development, and those acting via the activation of NF-B (Figure 2) (40, 61) .
The role of NF-B in promoting carcinogenesis of colorectal cancer
In chronic inflammation, the cytokines and chemokines produced by inflammatory cells, propagate a localized inflammatory response and also enhance the survival of premalignant cells by activating NF-B (62) . Activation of the IKK/NF-B pathway is one key survival mechanism in a variety of cancer types (63) (64) (65) (66) . Numerous studies have indicated that NF-B can block apoptosis by regulating the anti-apoptosis proteins such as inhibitor of apoptotic proteins (IAPs) (67) . Another mechanism whereby NF-B may inhibit apoptosis is through its ability to inhibit prolonged c-Jun N-terminal kinases (JNK) activation and accumulation of reactive oxygen species (ROS) (10) .
NF-B proteins were detected in the epithelial cells and macrophages from patients with UC, CD and unspecific colitis thus providing evidence for constitutive NF-B activation (68) (69) (70) , and these patients have been associated with an increased risk of developing colitis-associated cancer (54) . The proinflammatory stimuli such as bacterial products via Toll-like receptors or cytokines (e.g. TNF- and IL-1) induce NF-B activation in different cell types and the block of the NF-B signaling has been shown to suppress experimental colitis (68) . On the other hand, activated NF-B translocates into the nucleus inducing the expression of cytokines such as TNF- and IL-6, and chemokines, all contributing to the inflammation-related tissue damage. This elevated IKK/NF-B activity may lead to aberrant upregulation of certain tumorigenic, adhesion proteins, chemokines, and inhibitors of apoptosis that promote cell survival (63, 64) . Therefore, NF-B may contribute to the development of colitis associated colorectal cancer by sustaining the ongoing inflammatory process in the gut mucosa. Inactivation of the IB kinase/NF-B pathway at the site of inflammation has been shown to attenuate the formation of inflammation-associated tumors (7) . The experimental data obtained in animal model of colitis associated colorectal cancer, inhibition of interleukin 6 (IL-6) trans-signaling dramatically reduced the number and size of the colon cancer (71) . The IL-6 is a multifunctional NF-B-regulated cytokines that acts on epithelial and immune cells, and regulate preneoplastic growth during CRC tumorigenesis (43) . Activation of NF-B in epithelial cells is directly involved in the promotion and progression steps of colitis associated colorectal cancer. To investigate the role of NF-B in CRC development, conditional knockout mice lacking of the expression of IKKβ in the epithelial cells in AOM/DSS colitis associated CRC model was used by Greten et al. (72) , who demonstrated that the number of colon tumors reduced (but not tumor size), although inflammation was not reduced comparing wild type with knockout mice. They also showed that the decrease in tumor incidence was accompanied by increased epithelial apoptosis. These data indicated that NF-B activation is involved in the promotion phase of CRC development.
The role of NF-B in facilitating colorectal cancer maintenance and invasion NF-B has been shown to regulate many genes differently expressed and implicated in cell proliferation, tumorigenesis, and metastasis in cancer. Cyclin D1 and cMyc, two NF-B target genes have an important role in cell growth and proliferation (73, 74) , and key angiogenesis factors such as vascular endothelial growth factor (VEGF) and interleukin-8 (64), are directly or indirectly enhanced by NF-B activation. Cancer growth inhibition via NF-B inhibition has been shown in colon (75) , and the similar results has been shown in other several flavors of human neoplasia such as lung (76) and breast (77) . To investigate the role of NF-B in inflammation-induced tumor growth, one study of experimental murine colon cancer metastasis model revealed Volume 6 Number 5 October 2009 that lipopolysaccharide (LPS)-induced metastatic growth response depends on both TNF- production by host hematopoietic cells and NF-B activation in tumor cells. Inhibition of NF-B in both colon and mammary carcinoma cells converts the LPS-induced growth response to LPS-induced tumor regression (78) . This study confirmed that NF-B-induced inflammation is directly linked to growth stimulation of malignant cells. A further mechanism whereby NF-B might be involved is through binding to the promoter of Cyclin D1 and thus stimulating gene transcription (79) .
Formation of new blood vessels is essential for tumor progression, and has been shown to be dependent on growth factors (e.g., TNF, VEGF) and chemokines (e.g., monocyte chemoattractant protein-1, IL-8), which are upregulated by NF-B signaling (80, 81) . Cyclooxygenase 2 (COX2), a protein involved in inflammation, is increased in more aggressive forms of colorectal cancer, and is known to promote angiogenesis. It can be induced by NF-B (82). SC-514, an inhibitor of IKK, blocks the TNF--induced activation of NF-B as well as the expression of matrix metalloprotease-9 (MMP-9), migration and invasion of murine colon adenocarcinoma cells (83) .
To investigate the role of NF-B activation in tumorigenesis in a mouse model of CAC, the AOM/DSS model, tumor development was investigated in mice lacking IKK- expression restricted to myeloid cells or intestinal epithelial cells. Accordingly, these mice exhibited decline in tumor load, most of tumors presented in these mice were smaller in size compared to tumors in WT mice (72) , which indicates that the inflammation-related release of cytokines might target epithelium thus promoting the expansion of transformed cells in an NF-B dependent manner, the expression of most of cytokines and growth factors characterizing the inflammatory process and involved in tumor progression relies on NF-B activation in immune cells (84) . Taken 
NF-B inhibition: strategy for colorectal cancer therapy
The pivotal role of the NF-B signaling pathway in apoptosis, tumor promotion and tumor maintenance, strongly suggests that NF-B inhibitors would be useful in cancer therapy, and much efforts is currently invested in developing NF-B inhibitors in cancers (10, 14, 85, 86) . Several agents have been implemented to inhibit IKK/NF-B activity, because of the relevance of this process in cancer and those related with inflammation, such as curcumin, ginseng extract, resveratrol, green tea extract have anti-inflammatory and antiproliferative propertiese (87) . Proteosome inhibitors regulates the degradation of IB and hence inhibits NFB, and a few publications have documented their efficacy in triggering apoptosis in cancer cell lines in combination with either chemotherapeiutic drugs or death-inducing cytokines (88) (89) (90) . Sulfasalazine and methotrexate are widely used for treatment of acute states of IBD by inhibiting NF-B activation (91, 92) , thus, may also decrease the risk of developing cancer. NSAIDs and aspirin reduce the risk of gastric cancer in human and the incidence of colorectal cancer in animal models (93, 94) .
Concluding remarks
Colorectal cancer represents a life-threatening complication of inflammatory bowel diseases, and NF-B was natural suspects in providing a mechanistic link between inflammation and carcinogenesis. The molecular mechanisms underling this process have only recently started to be clarified with biochemical and genetic studies (95) . The results of Pikarsky et al. (8) , Greten et al. (72) , and Luo et al. (78) identified the NF-B signaling pathway could be regarded as a rational target for cancer therapy, and there is significant enthusiasm from cell culture experiments and animal models for the use of NF-B inhibitors as a new anti-cancer therapy in recent years (14, 96, 97) . However, several questions remain. First, the biggest question is whether this type of approach will be of general applicability. For example, IKK inhibitors more specifically inhibit IB phosphorylation and degradation, and subsequent classical NF-B signaling pathway that is initially implicated in colorectal cancer (10, 98) , but only partly inhibit NF-B activation, and do not appear functional in neck and head cancers (99) . Therefore, the specific roles of different NF-B subunits in different cancer types, especially in biological behavior (such as survival, proliferation, angiogenesis, differentiation, and metastasis) of malignancies, need to be explored further. The connection between inflammation and cancer is now generally accepted, but the question is that whether anti-inflammation is the best target for cancer therapy. An ideal NF-B inhibitor should prevent NF-B activation without any apparent effects on other signaling pathway and should avoid long-term immunosuppression.
